Full Year 2022 Genus PLC Earnings Presentation Basingstoke - Hampshire Sep 8, 2022 (Thomson StreetEvents) -- Edited Transcript of Genus PLC earnings conference call or presentation Thursday, September 8, 2022 at 6:01:00am GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Alison Henriksen Genus plc - CFO & Executive Director * Stephen Wilson Genus plc - CEO & Executive Director ================================================================================ Presentation -------------------------------------------------------------------------------- Stephen Wilson, Genus plc - CEO & Executive Director [1] -------------------------------------------------------------------------------- Welcome to our webcast of the Genus Preliminary Results for our 2022 fiscal year. Thank you for joining Alison Henriksen and me today. As well as our recorded webcast, there will be a live Q&A held later today and details are in our results release. So, after the usual disclaimer on Chart 2, I'm going to be covering our business and strategic progress, and Alison will outline the financial performance. But first, let me start with some headlines for Genus for fiscal year 2022. We continue to make good strategic progress, and we invested for the future while navigating a challenging macro environment. With the war in Ukraine were dramatic increases in input costs for protein producers. As anticipated when we announced our half year results, the porcine market in China continued to be challenging in the second half, exacerbated by COVID lockdowns there. As you can see from the headline numbers, this had a significant impact on our performance in the year, resulting in lower adjusted profit and earnings per share against the very strong prior year comparison. However, outside PIC China, Genus has performed strongly with revenue up 9% and adjusted profit up 28% despite the challenging external environment. Encouragingly, since June, we've seen an improvement in pig prices in China, and I will talk more about that shortly. I'd say our progress was really underpinned by market share gains with key customers globally, who are recognizing the strength of our genetics and the great services our Genus colleagues provide. And I'll illustrate some examples of that in the presentation. We've also been investing significantly in our supply chain and systems to support future growth, and I'm really pleased with the progress we've made. Our R&D programs also continue to make good progress. We have a growing pipeline of initiatives across different discovery and development stages. And our PRRSV resistance program is on track. So through the great commitment and contributions of Genus colleagues in pursuing our consistent strategy, we've continued to make progress through the year. And we're recommending a final dividend unchanged from last year, taking the total dividend for the year to 32p. So, now let's understand a bit more about what is happening in our customers' markets and the challenges they're facing. Looking around the world, North America is perhaps in the best shape for protein producers. While they are experiencing high input costs of grain, fuel and labor, output prices have also risen, creating profitable conditions for producers. However, they are generally cautious on expansion due to factors such as the high cost of construction, shortage of labor, or drought conditions in many beef raising areas. In Latin America, tough trading conditions in the second half of FY '22 were driven in part by lower exports to China of both pork and beef. Currently, we're seeing somewhat better signs around exports and an improved balance between input and output prices, though concerns remain about the strength of domestic demand. Conditions for our customers in Europe, across all categories, are really very tough. Which I'm sure is not surprising to you given the well-known issues with the Ukraine war, cost inflation, African swine fever spreading across Europe, and to cap it all the scorching summer drought that we experienced. Finally, in Asia, I'll deal more with the China porcine market on the next chart, but here, I'd comment that China dairy has been a favorable expansionary market environment, but is now turning to a more cautious, neutral phase. So to summarize, while the global picture is always complex, this has been a uniquely challenging environment for many of our customers. Let's look then in more detail at China porcine. I think those of you who follow Genus will be well aware that pig producers there have been heavily loss-making in FY '22. The chart on the left shows the ratio of pig price to corn price, which can be used as a rough rule of thumb on the profitability of production. A ratio of 6x is typically seen as a benchmark of breakeven. What you'll observe is that since June, the ratio has moved above this level. Although corn prices rose, they've been more than covered by the increase in the pig price above 20 RMB per kg. And actually in this last week, it was at 23 RMB per kg. And industry observers expect prices to hold above 20, at least for the remainder of this calendar year. So the move upwards is clearly encouraging. However, it typically takes some months of good prices before demand for porcine genetics improves. In managing our business in China, we continue to take the long view, and we're building our capacity to supply, both through third-party multiplication and owned and joint venture farms, in what is the world's biggest pig market. In addition, our team truly is incomparable to any others in the market, and our genetics are performing very well in customer systems. So we remain confident that we're very well placed to benefit from improving demand as and when it materializes. Let's now turn to see how we're winning with strategic customers around the world. And I'd like to start with PIC in North America. We're clearly gaining market share in both the sire line and dam line, based on the strength of our product performance backed up by outstanding technical service. The PIC800, which we introduced following the [Malavang] acquisition, is now used by 17 of the top 20 U.S. producers and is gaining share within these systems as they see its performance. Our overall market share gain in the sire line was an impressive 5 percentage points in the year. The Canberra sow continues to lead the market and has been at the forefront in capturing share from internal programs in North America. Most recently at Olymel, where our integration of their AlphaGene program got off to a very good start in the second half of FY '22. The results of these gains are now clearly showing through in accelerating North American volumes, and our fastest rate of royalty growth there, at 7%, for many years. Spain is the largest porcine market in Europe with a strong focus on technified production. We've been focused on growing our presence in this important market for several years, and the fruit of that is also now clearly coming through. Our volume growth is accelerating, and it's been driven by growth in royalties. Our strategy to win has focused on demonstrating performance at key customers, such as those highlighted on the chart, while growing our capacity to supply the market. Most recently, we've been particularly focused on creating more boar stud capacity with strong partnerships with Semen Cardona, a leading boar stud operator, and the Sergal acquisition, which performed well in its first year. All of this gives us confidence that there is considerable opportunity to continue to grow. Let's now switch our focus to ABS, where our strategy of driving growth in sexed and beef continue to show progress, with sexed and beef semen volumes exceeding 50% of global semen sales for the first time. The case study on the right is a great example of how we use our total ABS portfolio to drive value for strategic customers. Our relationship with this customer started about 4 to 5 years ago, through providing genetic advice and embryos to improve their herd quality. Next, we introduced Sexcel. Then, we conducted a trial with them of our new era beef and dairy genetics against Angus bulls. The result of that trial was so compelling that the customer decided to not only switch fully to a new era, but to retain and grow out the resulting calfs to capture the beef value. We then wrap great technical and reproductive service around the genetics, and that's further added to the customers' performance with the result that we now have essentially all of the customers' business. I mentioned earlier that China's dairy market has been growing. As you can see on the bottom left of the chart, with large-scale producers driving consolidation and modernization of the industry, ABS has achieved significant success there through our engagement with key accounts and supply chain partners. This has enabled us to rapidly gain share and, importantly, to also start to drive the growth of sexed semen, as you can see from the graph at the top left of the chart. Through examples, such as the case studies shown here, we've been able to move beyond the previously typical transactional buying behavior of China dairies, into more strategic genetics relationships. In the case of this inner Mongolia key account, we created a genetic index focused on the customers' objectives, and that's enabling us to drive and measure progress with the customer; leading them to increase the share of the business that we have in that account. In the second example, we're partnering with a leading global producer of dairy products to access a network of smaller farmers. These examples, I think, illustrate how we're achieving strong progress in our presence in the China dairy market. This year has been a year of significant investment in the business. Investment we've been making based on our confidence in the future growth opportunities for Genus. I've touched earlier on some of our M&A deals. So here, I'll focus on facilities and systems. You can see here in the middle, our new porcine elite farm in Saskatchewan called Atlas. This is now stocked and operational, and I was fortunate to be able to visit it, along with other Board members, in June. It's a great facility. We're using the opportunity of the greenfield site there to achieve an even higher health status of our genetics. I was also able to visit our new leads facility in Wisconsin, which first opened in 2021, and where further barns were added this year. It's a truly wonderful environment for our bulls to live in and be productive. At the same time as facilities, we've also invested in our systems. In ABS, we've introduced new approaches to digitally interacting with our customers, enhancing customer experience. And our Genus One rollout continues, with the U.K. successfully going live last month. Meaning that now over 60% of Genus is live on the system. As well as these capital investments, we also invest significantly in R&D, knowing that in our long-cycle business, it is important to consistently pursue the next opportunities for innovation that can drive future progress. PRRSV gene-edited pigs are an example many of you will be familiar with, and I'll comment on that on the next chart. Here, what I really want to highlight is that our pipeline of projects has grown significantly over the last 2 years as we've built out our R&D capabilities. And that pipeline now contains a broadly balanced set of opportunities over time and across discovery and development stages. Of course, scientific discovery and technical developments face many challenges on the way to eventual realization. And some projects, frankly, may not succeed. So we manage this very much as a portfolio of opportunities. Our PRRSV project continues to make steady progress in line with its plan. We're expanding our E2 generation animal numbers, and we'll be giving birth to E3 generation animals towards the end of this calendar year. We're commissioning an additional farm this autumn to house the growing number of animals, which will add to our gene editing expense in FY '23. Meanwhile, our productive relationship with the FDA continues, and we're expanding our regulatory engagement in other key countries. In addition, our engagement with supply chain participants, including producers and packers, is stepping up and the interest we see is encouraging. Finally, I'd like to wrap up this segment of the presentation by commenting on sustainability. The most important contribution we make to sustainability is the genetic improvement we deliver to our customer systems. Enabling them to produce protein with fewer resources, like less land, less water, and fewer emissions. I'm pleased to report that across pork, dairy, and beef, our teams again made strong progress in driving genetic improvement. This drives our results in making our products the best choice for customers and it benefits the environment. So, sustainability really is at the heart of what we at Genus do. However, we do also want to reduce the carbon emissions we're directly responsible for as a business through our own operations. And so we've set out some clear goals, and we're making strong progress. Our primary intensity ratio measures carbon emissions versus the weight of animals under our control. And that reduced further. We've now achieved a 25% cumulative reduction in carbon intensity since FY '19. Many factors drove this, including our animals' diet composition, manure management, more sustainable energy sourcing, and land management. And we have many actions in place to drive further gains over the coming years to meet our commitments. With that, I'd now like to hand over to Alison to take you through the financials. -------------------------------------------------------------------------------- Alison Henriksen, Genus plc - CFO & Executive Director [2] -------------------------------------------------------------------------------- Thank you, Stephen. This year, Genus had some particularly challenging market conditions, and I'm proud of the performance of the business and especially our colleagues in meeting these challenges, whilst keeping one eye on future growth. Milly, who features on this page symbolizes this. PIC don't normally name their pigs, but Milly is the one millionth piglet that was born at PIC's Apex Nucleus farm last year, and she gave birth to her first litter of 22 piglets. She's a special sow. But let's get on to the numbers. As you heard from Stephen, our full year results have been impacted by PIC China's performance, but there were robust performances across the rest of the group. In actual currency, adjusted profit before tax of GBP 71.5 million was down 16%. The graph to the right very clearly shows the decrease in trend of profit and operating profit margin. However, what you can also see is that despite the downturn in PIC China, our results were still higher than the profit and margin achieved in FY '21. And I'll talk more about the different regional performances in a moment. This year, there was a GBP 1.8 million exchange rate benefit on the translation of overseas profits, primarily from sterling weakening against other currencies. And this was particularly pronounced in the second half. At today's spot rates, we estimate that the benefit for FY '23 will be over GBP 6 million. The work of our R&D team is incredibly important, as you heard from Stephen, and they're making great progress with the PRRSV program and other opportunities. And thus, we invested GBP 67 million, which is up 7% on the prior year. I'll share some more of the specifics of this later. Central costs were 16% lower than prior year, reflecting prudent cost management given the challenges for PIC China, and we had lower performance-related employee rewards. Adjusted operating profit excluded gene editing costs was down GBP 11.8 million or 14% in constant currency. And I have talked previously about our target being 10% CAGR growth over the medium term, and I'll share more on this later. So for the rest of the presentation, I'll refer to constant currency growth, as I believe this is a better indicator of our underlying trading performance. Now turning to volumes. China has significant impact on our porcine volumes, which meant they were flat overall, but strong at 8% growth excluding China. And in bovine, we achieved record growth last year, and there have been more headwinds this year with the challenging macroeconomics in many markets. So against this tough compare, it was a robust performance, achieving 3% growth in the year. Consistent with the first half, this was led by beef and sexed genetics. And from a regional perspective, Asia led the way in growth. Now, what I want to do here is pull the numbers apart to show you what happened in PIC China versus the rest of the group. And in the graph on the left, you can see the adjusted operating profit trend of Genus, excluding PIC China and gene editing costs. 25% growth was achieved in the year, which is higher than 17% growth achieved in FY '21. And at the same time, there has been growth in profitability, with margin improving over 150 basis points in each of the past 2 years. On the right-hand side of this slide, you can see what's happened to PIC China's performance. The graph on the top shows the causes of year-on-year decline in PIC China's profit from circa GBP 33 million to under GBP 6 million in the year. Similarly to the first half, there was a loss of profits from the reduction in upfront sales and royalty contracts. Higher supply chain costs were incurred due to the closure of an aging facility in the first half and expansion of another in the year. And also by-product sales were over GBP 4 million lower with the average pig price down 50% to below RMB 15 per kilo compared to a peak of RMB 35 per kilo back in December 2020, which really provided unusually high profits for FY '21. PIC China's profits were also impacted by a charge of GBP 4 million, which was a one-off refund to a customer that we talked about in the first half when it was concluded. The graph in the bottom right shows the volume trends, where you can see in the second half, volume remained low compared to prior year, down by 42%. However, volumes improved 19% in the second half in comparison to the first half, reflecting higher sales under royalty contracts to customers that commenced populating their farms. It's still very early days in the recovery of the porcine market. But as you can see, we now have a much larger business than in FY '19, when African swine fever first occurred in China. But most importantly, the PIC China team have done a great job the past year, positioning the business for the recovery. The last of the supply chain changes is the new farm in Ankang that will be stopped in November. So as you can see, PIC's profit declined 13%, but increased 11% if China is excluded. Royalty revenue was up 1% for the year, but up 8% if China is excluded. The loss of profits in China meant PIC lost some leverage of its cost base; and its adjusted operating profit margin dropped to 36.6%. And you heard from Stephen how North America has continued to achieve strong growth in the second half, taking market share, which led to very good growth in operating profit: up 7% on prior year, the highest rate of growth they have achieved for more than 5 years. And royalty revenue growth was also strong at 7%, and we expect more growth to come. Latin America also performed well, with profit up 5%. But as I warned in February, Brazil had a tougher second half as customers were cautious given the drop in exports to China. Our joint venture with Agroceres saw profit drop 7% for the year. Europe's profit was slightly up on prior year, and we've continued to operate in Russia. But profit was down 27% on prior year, when there was a large expansion with a key account in Russia. As you heard from Stephen, Spain has continued to be the growth driver for the region, up 40%. This underpins Europe's royalty revenue growth of 7%, which is very encouraging. And lastly, as you've heard, China overshadowed Asia's results, but the rest of the region achieved strong growth of 25%, with the Philippines being a key contributor, achieving 67% growth as the country recovers from ASF. Now ABS' revenue growth was 7% and adjusted operating profit growth was 9%. Performance was softer in the second half, and this is due to the challenging market conditions, particularly following the Russian invasion of Ukraine. And there was an impact of an IT security incident in June, which had an impact on Latin America. North America's sexcel volumes grew 10% and new era beef volumes were very strong at 33%. Embryo volumes also recovered in the second half. Revenue grew 4%, and this reflects the volume growth and also growth in intelligent third-party business. The mix effect of revenues, combined with sound management of pricing to offset some cost inflation, meant North America's profit was up 4%. Latin America continued to grow, delivering a 5% increase in revenue and 2% increase in operating profit. It was certainly a tougher year for our team, and this is due to a temporary ban on beef exports to China in the first half. And in the second half, June trading was significantly impacted in Brazil due to a cyberattack that hampered the team's ability to dispatch product in that month. We estimate the impact on trading was just shy of GBP 1 million, which means that if that hadn't happened, LatAm would have achieved operating profit growth of 11% for the year. And I do want to mention that the cyberattack affected some legacy systems only. Our Genus One ERP was secure, and the impact was only in the month of June. It's just unfortunate, and this is a common occurrence for companies these day. But I want to acknowledge that the situation was extremely well managed by our IT team, and we further bolstered our IT security. EMEA's revenue was up 5%, even though total volumes were down 2%, and that's because there's been sound management of pricing to offset inflation and good growth in our intelligent third-party business. Sexcel continued to grow at 8%, and beef volumes were up 9%. But the market uncertainties, particularly triggered in the second half by the Russia-Ukraine conflict, meant overall volumes and profit were impacted in the U.K. and in our distributor markets. And consequently, operating profit was down 4% for the region for the year. ABS continues to operate in Russia and the Ukraine. And I just think it's quite remarkable that despite facing enormous challenges, our colleagues in the Ukraine beat their budget for the year. Asia continued to achieve high growth in operating profit, up 24%. And as you heard from Stephen, ABS is doing very well in China, with profit up 40%. Now overall, R&D increased as planned to GBP 67 million. And that's despite the challenging year we've had. We've stuck to our strategy, investing in R&D. And as Steve illustrated, the increase in spend in the past 3 years has really translated into a growing pipeline of opportunities. Porcine product development was stable as was our spending on gene editing. However, we do expect that gene editing costs will increase by GBP 5 million to GBP 6 million in constant currency in FY '23, as we increase the numbers of edited animals and get closer to completing our FDA submissions. We also expect porcine product development cost to increase in FY '23 by around GBP 6 million, which reflects the expansion of PIC supply chain with the opening of the Atlas Nucleus farm. Bovine product development spend was up 13%, and that reflects the continued investment in our intelligent production capacity and our dairy and beef development programs, particularly New Era, with it now accounting for a third of beef volumes. So moving on to statutory income. We consistently measure and report our adjusted results as we do think these give a better understanding of the business' underlying performance. Our statutory results were affected by a number of noncash items, and I'll walk you through these. Statutory profit before tax decreased to GBP 48.4 million, and profit after tax on a statutory basis was GBP 36.7 million. The adjusted tax rate was 24.3%, and that's up 180 basis points on last year; which is due to the reduced share of group profits arising from China, where we have a benefit from the availability of tax relief on certain agricultural-related activities. The effective statutory tax rate was also higher at 28%. again, due to the mix of China profits. And there was a one-off charge reflecting higher deferred tax rates on the porcine biological assets in China. Those of you that are familiar with our accounts will know that we are required in our statutory accounts to apply IAS 41 accounting for biological assets. And the effect was a GBP 5.4 million decrease, which is due to the reduction in the fair value of bovine assets due to certain fair value estimate changes. As those of you who follow the company know, these fair value calculations can fluctuate and are noncash movements. Exceptional items are lower with income of GBP 3.6 million from a legacy legal claim in Brazil which we had in the first half, and that offset legal costs of GBP 1.4 million in relation to the ongoing litigation with ST Genetics. And ABS had supply chain restructuring costs of GBP 2.8 million. With the expansion of leads in Wisconsin, ABS was able to consolidate and close its barns in Canada. And lastly, the share of post-tax profits of the JVs was GBP 5.2 million. That is GBP 8 million down on prior year, reflecting the weaker performance of our JVs in China and Brazil, and also biological asset movements in the JVs. So, FY '22 was a big year of investment for us. It was a peak year for capital expenditure of almost GBP 51 million, which meant we had a cash outflow of GBP 13.5 million, and we spent GBP 19.5 million on investments that included the Olymel transaction, which we completed in February. You can see on this chart, we ended the year with net debt of GBP 185 million, which compares with almost GBP 106 million at the beginning of the financial year. Our leverage has increased to 1.7x EBITDA but remains within our targeted range of 1 to 2x. Cash generated by operations of GBP 59.7 million reflected cash conversion of 82%. This is an improvement on the first half, although a little below our annual target of 90%. At the 30th of June, the headroom of our credit facilities was almost GBP 78 million. And subsequently in August, we exercised the accordion in our facilities and drew down the equivalent of GBP 60 million, and extended the term a further year to August 2025. This gives us headroom more in keeping with historic levels. The first half of our financial year is less cash generative. And with the recent weakening of sterling against the U.S. dollar also impacting our U.S. borrowings, I would expect our net debt to EBITDA to increase to above 2x by the middle of the financial year before returning at the full year to around the current level. With the increased debt and higher interest rates, I expect we will also have higher finance costs in FY '23, up by around GBP 4 million. So, given our solid financial performance, we are pleased to propose our final dividend remains flat compared with prior year, which is 2.6x adjusted earnings cover, and that's within our targeted range of 2.5 to 3x. While 2022 has been a challenging year, we need to put it in context of Genus' medium-term financial objectives. When referring to our 5-year profit CAGR performances, you can see we've delivered against our target of 10%. There are a few ups and downs in annual cash conversion, but our 5-year average is over 100%. So, despite the various macroeconomic challenges in various parts of the world, our stated financial objectives remain the same, and we've continued to manage the company with our focus on the medium- and long-term growth opportunities. So, thank you for listening. And I'll now hand over to Stephen to conclude our presentation. -------------------------------------------------------------------------------- Stephen Wilson, Genus plc - CEO & Executive Director [3] -------------------------------------------------------------------------------- Thank you, Alison, for taking us through the financials. We've covered a lot in this presentation. So, I'll try and summarize briefly. As we've seen, our performance in FY '22 was heavily impacted by the porcine market in China, but has been strong excluding it. We've been making continued good strategic progress and have invested for growth. I think we're all aware that the macro landscape that companies are navigating has many challenges, both economic and political. More positively, we've seen recent improvement in the China porcine market, and we're well positioned to benefit as and when demand for genetics improves. You've seen from Alison our performance against our stated medium-term growth expectations. And looking forward, those expectations remain unchanged, which reflects our confidence in Genus' strategy and the many opportunities we have for growth. So, let me just thank you for your time today.

Bill Gates looks for income, too. This is how he gets it.

As we close in on the final quarter of 2022, investors are looking for an answer to one question: was June’s low the bottom for stocks, or do they have more room to fall? It’s a serious question, and there may be no easy answer. Markets are facing a series of headwinds, from the high inflation and rising interest rates that we’ve grown familiar with to an increasingly strong dollar that will put pressure on the upcoming Q3 earnings. Weighing in on current conditions from Charles Schwab, the $8 t

The bad news just doesn't seem to be stopping for Nvidia (NASDAQ: NVDA). The graphics cards specialist received another big blow last week after the U.S. government imposed restrictions on sales of data center chips to China, Hong Kong, and Russia. According to a filing with the SEC, Nvidia reported that the U.S. government has "imposed a new license requirement, effective immediately, for any future export to China (including Hong Kong) and Russia of the Company's A100 and forthcoming H100 integrated circuits."

Tough times ahead. But you don't need to sell it all.

The S&P 500 is on again, off again all year. But investors clearly have a "buy list" of stocks they want to own when the rally looks real.

Verizon Communications Inc.'s ( NYSE:VZ ) periodic dividend will be increasing on the 1st of November to $0.6525, with...

Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett is one of the best investors of our lifetime. Buffett stands out, in part, because he doesn't tend to follow the crowd, doesn't fear market crashes, and has a knack for putting his cash to work when everyone else is fearful. Buffett has explained that he looks to buy quality companies with management teams he likes and that he buys with the intention of holding on to these investments for years or even decades.

BullsEyeOption.com Chief Market Strategist Alan Knuckman joins Yahoo Finance Live to discuss energy markets and how Europe's energy crisis could impact both the U.S. and China.

It's time to be extra picky.

Devon Energy (DVN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AT&T income-hungry shareholders should have seen it coming. In April last year, a month before announcing the spinoff of its media division to shareholders in the form of shares of a 71% stake in the newly created Warner Bros. Discovery Chief Executive Officer John Stankey assured investors that “our deliberate capital-allocation plan allowed us to invest and sustain our dividend at current levels, which we believe is attractive.” AT&T’s eventual failure to raise the dividend in 2021 broke a 34-year streak and saw it booted out of the vaunted S&P 500 Dividend Aristocrats Index.

Berkshire Hathaway is on pace to collect $6.07 billion in dividend income over the next 12 months. Just five holdings will account for 71% of total payouts.

(Bloomberg) -- In a week that saw discretionary buyers beat a quick retreat from risky assets, another set of traders stood up to halt a three-week plunge in the S&P 500: those with little choice but to buy.Most Read from BloombergCharles Becomes King as the Face of a Nation ChangesUkraine Army’s Breakthrough in North Threatens Russian GripDouble Rainbow Appears Over Buckingham Palace as Crowd Gathers to Mourn QueenForced Buying Puts a Floor Under Stocks Nobody Else Wants to OwnQueen Elizabeth’s

DocuSign's (NASDAQ: DOCU) stock surged 10.5% the day after the release of its fiscal 2023 second-quarter earnings report. For the third quarter, DocuSign expects revenue to rise 14% to 15% year over year as billings increase 3% to 5%. DocuSign's stock is down by nearly 80% from the all-time high of $310.05 it touched last September, but it remains over 120% above its IPO price of $29.

Annaly Capital Management (NLY) closed at $6.65 in the latest trading session, marking a -0.15% move from the prior day.

The Coca-Cola Company ( NYSE:KO ) stock is about to trade ex-dividend in four days. Typically, the ex-dividend date is...

In this article, we discuss 10 dividend stocks with over 8% yield to buy in September. You can skip our detailed analysis of top high dividend stocks, and go directly to read 5 Best Dividend Stocks with Over 8% Yield You Can Buy in September. In the current market situation, investors are looking for different […]

In this article, we will look at 10 stocks that Jim Cramer is talking about in September. If you want to explore more stocks that journalist investor, Jim Cramer, is talking about in September, you can also take a look at Jim Cramer is Talking About These 5 Stocks in September. Jim Cramer has acquired […]

FuelCell Energy (FCEL) posts wider-than-expected fiscal Q3 loss. FCEL's backlog remains strong and the company continues to deliver modules and meet customer needs through clean energy generation.

Today's video focuses on Shopify (NYSE: SHOP) and recent updates affecting the company. The most recent update is the change in some of its leadership positions. More importantly, I share some bearish and bullish thoughts on the stock.